Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as…
Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023 September 28, 2022 07:30 ET | Source: Altimmune, Inc GAITHERSBURG,…